Skip to main navigation Skip to main content
  • E-Submission
  • Contact us

NS : Neurospine

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR AUTHORS

Articles

Page Path

Original Article
Minimally Invasive Spinal Surgery SMISS-Neurospine Special Issue

Higher American Society of Anesthesiologists Classification Does Not Limit Safety or Improvement Following Minimally Invasive Transforaminal Lumbar Interbody Fusion

Neurospine 2022;19(3):533-543.
Published online: January 2, 2022

Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA

Corresponding Author Kern Singh Department of Orthopaedic Surgery, Rush University Medical Center, 1611 W. Harrison St, Suite #300, Chicago, IL 60612, USA Email: kern.singh@rushortho.com
• Received: January 21, 2021   • Revised: April 7, 2021   • Accepted: April 28, 2021

Copyright © 2022 by the Korean Spinal Neurosurgery Society

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 8,762 Views
  • 199 Download
  • 7 Web of Science
  • 7 Crossref
  • 7 Scopus
prev next

Citations

Citations to this article as recorded by  Crossref logo
  • Risk Scale to Guide Prophylactic Paraspinous Flap Closure in High-Risk Spine Surgery
    Allison S. Karwoski, Esther Jung, Kevin Schlidt, Yvonne M. Rasko
    Journal of Reconstructive Microsurgery.2026;[Epub]     CrossRef
  • A Higher American Society of Anesthesiologists Classification Does Not Correlate With Inferior Outcomes Following Cervical Disk Replacement
    Shriya N. Patel, Sloane O. Ward, Nathaniel S. Cohen, Thomas J. Turinske, Kern Singh
    Clinical Spine Surgery.2026; 39(6): 304.     CrossRef
  • Baseline American Society of Anesthesiologists classification predicts worse anxiety and pain interference following Lumbar Interbody Fusion
    John F. Sencaj, Malik A. Siddique, Gregory A. Snigur, Sloane O. Ward, Shriya N. Patel, Kern Singh
    Journal of Clinical Neuroscience.2025; 131: 110929.     CrossRef
  • Music therapy combined with anesthesia recovery care boosts anesthesia recovery in colorectal cancer patients undergoing laparoscopic radical resection
    Yan Zheng, Hai-Fang Ni, Yan Shi, Dan-Qian Cui, Zhen-Zhu Wu, Yu-Feng Ling, Shui-Qing He, Xiao-Yun Qin
    World Journal of Gastrointestinal Surgery.2025;[Epub]     CrossRef
  • What Are the Risk Factors for Mechanical Failure in Spinal Arthrodesis? An Observational Study
    Vincenzo Peccerillo, Antonio Culcasi, Riccardo Ruisi, Francesca Amaducci, Maria Grazia Benedetti, Marco Girolami, Andrea Evangelista, Mattia Morri
    Surgical Techniques Development.2024; 13(1): 87.     CrossRef
  • Efficacy of polidocanol foam sclerotherapy in treatment of patients with advanced hemorrhoids
    Zhen-Jun Fang, Lin-Xue Wang, Fa Jin
    World Chinese Journal of Digestology.2024; 32(5): 361.     CrossRef
  • Periotome versus piezotome as an aid for atraumatic extraction: a randomized controlled trial
    Mohammed Abdullah Alraqibah, Jingade Krishnojirao Dayashankara Rao, Bader Massad Alharbi
    Journal of the Korean Association of Oral and Maxillofacial Surgeons.2022; 48(6): 356.     CrossRef

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Higher American Society of Anesthesiologists Classification Does Not Limit Safety or Improvement Following Minimally Invasive Transforaminal Lumbar Interbody Fusion
Neurospine. 2022;19(3):533-543.   Published online January 2, 2022
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Higher American Society of Anesthesiologists Classification Does Not Limit Safety or Improvement Following Minimally Invasive Transforaminal Lumbar Interbody Fusion
Neurospine. 2022;19(3):533-543.   Published online January 2, 2022
Close
Higher American Society of Anesthesiologists Classification Does Not Limit Safety or Improvement Following Minimally Invasive Transforaminal Lumbar Interbody Fusion
Higher American Society of Anesthesiologists Classification Does Not Limit Safety or Improvement Following Minimally Invasive Transforaminal Lumbar Interbody Fusion
Characteristic Total (n=487) ASA PS classification
p-value
I (n = 64) II (n = 336) III+ (n = 87)
Age (yr) 52.1 ± 11.7 42.1 ± 10.2 52.4 ± 11.1 58.1 ± 10.1 < 0.001*
Sex 0.083
 Female 209 (42.9) 21 (32.8) 155 (46.1) 33 (37.9)
 Male 278 (57.1) 43 (67.2) 181 (53.9) 54 (62.1)
Body mass index (kg/m2) < 0.001*
 < 30 260 (53.4) 45 (70.3) 189 (56.3) 26 (29.9)
 ≥ 30 227 (46.6) 19 (29.7) 147 (43.8) 61 (70.1)
Smoking status 0.776
 Nonsmoker 404 (83) 54 (84.4) 280 (83.3) 70 (80.5)
 Smoker 83 (17) 10 (15.6) 56 (16.7) 17 (19.5)
Insurance 0.003*
 Non-WC 311 (63.9) 29 (45.3) 227 (67.6) 55 (63.2)
 WC 176 (36.1) 35 (54.7) 109 (32.4) 32 (36.8)
Medical diagnosis
 Diabetes mellitus 58 (11.9) 0 (0) 30 (8.9) 28 (32.2) < 0.001*
 AIDS 0 (0) 0 (0) 0 (0) 0 (0) -
 Myocardial infarction 5 (1) 0 (0) 1 (0.3) 4 (4.6) 0.001*
 Hypertension 177 (36.4) 4 (6.3) 113 (33.7) 60 (69) < 0.001*
 Neurological disease 9 (1.9) 0 (0) 2 (0.6) 1 (8.1) < 0.001*
 Arthritis 87 (17.9) 1 (1.6) 63 (18.8) 23 (26.4) < 0.001*
 Congestive heart failure 5 (1) 1 (1.6) 1 (0.3) 3 (3.5) 0.031*
 PVD 9 (1.9) 0 (0) 4 (1.2) 5 (5.7) 0.010*
 Metastasis 0 (0) 0 (0) 0 (0) 0 (0) -
 Liver disease 5 (1) 0 (0) 5 (1.5) 0 (0) 0.320
 Renal failure 4 (0.8) 0 (0) 2 (0.6) 2 (2.3) 0.216
 Chronic lung disease 32 (6.6) 0 (0) 24 (7.2) 8 (9.2) 0.059
 GI bleed 1 (0.21) 0 (0) 0 (0) 1 (1.1) 0.100
Characteristic Total (n = 487) ASA PS classification
p-value
I (n=64) II (n=336) III+ (n=87)
Spinal pathology
 Recurrent HNP 31 (6.4) 5 (7.8) 20 (6.0) 6 (6.9) 0.834
 Degenerative spondylolisthesis 263 (65.8) 27 (58.7) 188 (67.6) 48 (63.2) 0.432
 Isthmic spondylolisthesis 127 (31.8) 19 (40.4) 843 (0.3) 24 (31.6) 0.388
Operative time (min) 127.9 ± 35.8 122.9 ± 32.2 126.3 ± 35.3 137.9 ± 38.6 0.013*
Estimated blood loss (mL) 68.6 ± 69.5 62.8 ± 44.4 69.3 ± 74.9 69.7 ± 62.2 0.792
Length of stay (hr) 50.5 ± 38.1 46.2 ± 30.0 49.3 ± 37.8 58.4 ± 43.3 0.089
Complication Total (n = 487) ASA PS classification
p-value
I (n = 64) II (n = 336) III+ (n = 87)
Aspiration/reintubation 0 (0) 0 (0) 0 (0) 0 (0) -
Urinary retention 5 (1) 0 (0) 4 (1.2) 1 (1.2) 0.999
UTI 3 (0.6) 0 (0) 3 (0.9) 0 (0) 0.999
Epidural hematoma 2 (0.4) 0 (0) 2 (0.6) 0 (0) 0.999
Acute renal failure 1 (0.2) 0 (0) 1 (0.3) 0 (0) 0.999
Postoperative anemia 3 (0.6) 0 (0) 2 (0.6) 0 (0) 0.672
Altered mental status 1 (0.2) 0 (0) 0 (0) 1 (1.2) 0.310
Arrhythmia 1 (0.2) 0 (0) 0 (0) 1 (1.2) 0.310
Ileus 1 (0.2) 0 (0) 1 (0.3) 0 (0) 0.999
Atelectasis 1 (0.2) 1 (1.6) 0 (0) 0 (0) 0.131
Pancreatitis 1 (0.2) 0 (0) 1 (0.3) 0 (0) 0.999
Total 19 (3.9) 1 (1.6) 14 (4.2) 3 (3.4) 0.593
Urinary retention 5 Patients with significantly elevated PVR required a foley catheter upon discharge but discontinued use by first follow-up appointment.
UTI 3 Patients developed a urinary tract infection and were discharged on antibiotics
Epidural hematoma 2 Patients developed epidural hematomas, underwent evacuation, and were discharged in stable condition
Acute renal failure 1 Patient had acute tubular necrosis on POD1 with a Cr increased 2-fold from baseline on POD4. Monitored in medical ICU until Cr dropped to 2.2 and was discharged safely to a rehab facility.
Postoperative anemia 2 Patients required transfusion with 1 unit of PRBC, 1 patient with 2 units. All patients were discharged in stable condition.
Altered mental status 1 Patient experienced recurrent staring episodes on POD1. CT scan was concerning for subarachnoid hemorrhage and was transferred to neuro ICU with a negative workup. Mental status returned to baseline on POD6 and was transferred to a rehab facility for concerns of alcohol withdrawal
Arrhythmia 1 Patient had atrial fibrillation with RVR on POD1, underwent TTE and cardioversion. Discharged in stable condition and followed up with PCP and cardiology.
Ileus 1 Patient experienced abdominal distention on POD3. Gastroenterology consulted. Rectal tube was placed to decompress the large bowel. Patient was tolerating a regular diet by discharge.
Atelectasis Linear opacities were identified on chest x-ray with low lung volumes consistent with atelectasis; patient was discharged in stable condition to follow up with sleep study.
Pancreatitis 1 Patient had elevated lipase and was thought to be suffering from mild pancreatitis. Lipase significantly decreased by discharge and instructed to follow up with gastroenterology.
PROM ASA PS classification
p-value
I II III+
VAS back
 Preoperative 6.7 ± 1.5 6.7 ± 2.2 6.6 ± 2.6 0.939
 6 Weeks 3.9 ± 2.1 3.9 ± 2.4 3.9 ± 2.6 0.981
 12 Weeks 3.6 ± 2.8 3.6 ± 2.5 4.0 ± 2.6 0.479
 6 Months 3.8 ± 2.9 3.5 ± 2.6 3.9 ± 2.9 0.439
 1 Year 2.2 ± 2.3 3.0 ± 2.5 4.1 ± 2.8 0.126
 2 Years 3.8 ± 3.1 3.4 ± 2.9 4.7 ± 3.3 0.367
VAS leg
 Preoperative 4.5 ± 3.2 5.6 ± 2.9 5.6 ± 2.8 0.230
 6 Weeks 2.3 ± 3.1 3.2 ± 2.8 3.2 ± 3.2 0.356
 12 Weeks 2.7 ± 3.0 2.8 ± 2.7 3.1 ± 2.8 0.798
 6 Months 2.1 ± 3.2 2.6 ± 2.7 2.9 ± 2.9 0.553
 1 Year 1.3 ± 1.7 2.7 ± 2.9 2.1 ± 2.8 0.274
 2 Years 1.9 ± 2.7 2.6 ± 2.8 4.0 ± 3.6 0.264
ODI
 Preoperative 38.5 ± 17.4 40.9 ± 16.3 44.2 ± 14.5 0.553
 6 Weeks 33.9 ± 23.0 35.4 ± 18.7 40.4 ± 17.7 0.274
 12 Weeks 27.6 ± 20.4 29.5 ± 18.4 36.0 ± 18.6 0.130
 6 Months 21.9 ± 21.8 24.3 ± 18.8 31.5 ± 19.5 0.097
 1 Year 20.4 ± 15.4 24.3 ± 22.3 27.3 ± 21.8 0.658
 2 Years 21.7 ± 17.6 23.4 ± 20.2 33.9 ± 30.0 0.302
SF-12 PCS
 Preoperative 33.3 ± 7.5 31.5 ± 9.0 29.0 ± 10.1 0.149
 6 Weeks 33.4 ± 9.2 31.8 ± 8.5 28.1 ± 8.5 0.074
 12 Weeks 38.5 ± 9.8 35.0 ± 9.8 32.6 ± 10.8 0.183
 6 Months 44.7 ± 9.1 39.2 ± 11.3 34.7 ± 11.8 0.032
 1 Year 42.0 ± 10.3 40.7 ± 12.3 37.2 ± 10.1 0.436
 2 Years 46.0 ± 7.8 41.1 ± 11.5 33.4 ± 11.5 0.087
PROMIS PF
 Preoperative 37.1 ± 6.4 35.7 ± 6.2 34.5 ± 5.3 0.387
 6 Weeks 40.2 ± 7.0 38.0 ± 7.1 34.9 ± 6.6 0.103
 12 Weeks 43.9 ± 7.6 40.8 ± 7.3 41.0 ± 7.5 0.397
 6 Months 47.0 ± 5.7 44.3 ± 7.1 40.5 ± 7.5 0.066
 1 Year 47.4 ± 11.3 46.1 ± 9.3 40.8 ± 10.0 0.126
 2 Years 48.6 ± 4.1 44.7 ± 9.5 36.7 ± 8.2 0.088
PROM ASA PS classification
p-value
I II III+
ΔVAS back
 6 Weeks 2.9 ± 2.1 2.8 ± 2.8 2.7 ± 2.9 0.918
 12 Weeks 3.0 ± 2.4 3.1 ± 2.8 2.5 ± 3.0 0.330
 6 Months 2.9 ± 2.6 3.1 ± 3.0 2.6 ± 3.0 0.435
 1 Year 4.5 ± 2.8 3.3 ± 3.1 2.6 ± 2.8 0.296
 2 Years 3.2 ± 3.3 3.3 ± 3.2 1.9 ± 3.0 0.426
ΔVAS leg
 6 Weeks 1.9 ± 3.2 2.6 ± 3.3 2.4 ± 2.9 0.589
 12 Weeks 2.3 ± 3.0 3.0 ± 3.1 2.6 ± 2.9 0.533
 6 Months 1.8 ± 2.7 2.9 ± 3.3 2.6 ± 3.0 0.407
 1 Year 2.5 ± 2.4 3.2 ± 3.1 2.8 ± 3.0 0.748
 2 Years 2.4 ± 2.5 3.6 ± 2.7 2.2 ± 3.2 0.253
ΔODI
 6 Weeks 6.6 ± 20.8 7.2 ± 18.6 4.4 ± 16.1 0.708
 12 Weeks 10.3 ± 13.8 13.3 ± 17.6 8.5 ± 14.5 0.281
 6 Months 12.6 ± 19.0 17.1 ± 18.3 14.4 ± 12.9 0.498
 1 Year 18.2 ± 15.7 17.9 ± 18.8 18.5 ± 15.4 0.992
 2 Years 17.6 ± 19.8 17.6 ± 17.3 12.7 ± 28.7 0.763
ΔSF-12 PCS
 6 Weeks 2.0 ± 11.6 1.3 ± 8.3 -0.7 ± 7.8 0.536
 12 Weeks 7.0 ± 10.9 4.9 ± 9.5 3.5 ± 11.7 0.611
 6 Months 11.8 ± 5.9 8.7 ± 11.4 5.4 ± 9.6 0.320
 1 Year 13.5 ± 9.6 10.8 ± 10.4 9.8 ± 9.6 0.748
 2 Years 8.1 ± 7.1 9.2 ± 10.5 6.2 ± 10.2 0.687
ΔPROMIS PF
 6 Weeks 2.3 ± 5.8 2.3 ± 6.6 0.4 ± 4.9 0.501
 12 Weeks 4.9 ± 5.7 5.7 ± 7.3 5.3 ± 5.5 0.937
 6 Months 8.2 ± 5.5 8.5 ± 8.1 6.1 ± 4.0 0.537
 1 Year 8.7 ± 6.4 10.8 ± 8.3 7.0 ± 5.8 0.245
 2 Years 8.7 ± 6.3 9.0 ± 9.2 6.0 ± 5.5 0.775
PROM ASA PS classification
p-value
I II III+
VAS back
 6 Weeks 31 (60.8) 155 (56.2) 41 (56.2) 0.651
 12 Weeks 25 (55.6) 150 (57.9) 30 (46.9) 0.280
 6 Months 24 (54.6) 151 (59.9) 30 (50.9) 0.594
 1 Year 6 (66.7) 52 (63.4) 5 (31.3) 0.041*
 2 Years 3 (42.9) 30 (58.8) 5 (41.7) 0.740
 Overall 39 (72.2) 227 (76.4) 54 (70.1) 0.657
VAS leg
 6 Weeks 4 (19.1) 38 (27) 7 (19.4) 0.825
 12 Weeks 3 (17.7) 41 (29.9) 10 (28.6) 0.562
 6 Months 2 (12.5) 38 (27.3) 8 (26.7) 0.421
 1 Year 2 (22.2) 26 (31.3) 3 (18.8) 0.653
 2 Years 1 (20.0) 15 (31.3) 3 (27.3) 0.903
 Overall 7 (29.2) 71 (44.1) 15 (37.5) 0.723
ODI
 6 Weeks 10 (45.5) 68 (46.6) 11 (29.7) 0.146
 12 Weeks 7 (43.8) 82 (58.6) 15 (41.7) 0.422
 6 Months 11 (68.8) 95 (67.4) 22 (71.0) 0.803
 1 Year 6 (66.7) 58 (69.1) 11 (73.3) 0.710
 2 Years 3 (60.0) 32 (65.3) 7 (63.6) 0.948
 Overall 17 (70.8) 128 (77.6) 32 (78.1) 0.569
SF-12 PCS
 6 Weeks 10 (52.6) 42 (41.6) 8 (33.3) 0.209
 12 Weeks 9 (75.0) 52 (53.1) 13 (56.5) 0.466
 6 Months 9 (90.0) 61 (63.5) 11 (64.7) 0.289
 1 Year 6 (100) 61 (74.4) 13 (76.5) 0.489
 2 Years 3 (100) 48 (75.0) 6 (54.6) 0.084
 Overall 20 (95.2) 101 (77.7) 25 (78.1) 0.196
PROMIS PF
 6 Weeks 7 (50.0) 26 (36.1) 4 (23.5) 0.131
 12 Weeks 7 (63.6) 32 (52.5) 10 (66.7) 0.767
 6 Months 8 (88.9) 37 (66.1) 8 (57.1) 0.140
 1 Year 6 (66.7) 38 (80.9) 10 (71.4) 0.943
 2 Years 3 (75.0) 34 (70.8) 3 (60.0) 0.610
 Overall 16 (88.9) 65 (75.6) 15 (75.0) 0.324
Table 1. Patient demographics and baseline characteristics

Values are presented as mean±standard deviation or number (%).

ASA PS, American Society of Anesthesiologists physical status; WC, workers’ compensation; AIDS, acute immune deficiency syndrome; PVD, peripheral vascular disease; GI, gastrointestinal.

p<0.05, statistically significant differences.

p-values calculated using 1-way analysis of variance (continuous) or chi-square analysis (categorical).

Table 2. Perioperative characteristics

Values are presented as number (%) or mean±standard deviation.

ASA PS, American Society of Anesthesiologists physical status; HNP, herniated nucleus pulposus.

p<0.05, statistically significant differences.

p-values calculated using 1-way analysis of variance (continuous) or chi-square analysis (categorical).

Table 3. Postoperative complications

Values are presented as number (%).

ASA PS, American Society of Anesthesiologists physical status; UTI, urinary tract infection.

p-value calculated using Fisher exact test.

Patients did not have complications associated with a venous thromboembolism, pulmonary embolism, pneumothorax, pneumonia, pleural effusion, or fever of unknown origin.

Table 4. Individual incidences of complications and associated outcomes

PVR, postvoid residual volume; UTI, urinary tract infection; POD, postoperative day; Cr, creatinine; ICU, intensive care unit; PRBC, packed red blood cells; CT, computed tomography; RVR, rapid ventricular response; TTE, transthoracic echocardiogram; PCP, primary care physician.

Table 5. Patient-reported outcomes

Values are presented as mean±standard deviation.

PROM, patient-reported outcome measure; ASA PS, American Society of Anesthesiologists physical status; VAS, visual analogue scale; ODI, Oswestry Disability Index; SF-12 PCS, 12-item Short Form health survey physical composite score; PROMIS PF, Patient-Reported Outcomes Measurement Information System physical function.

p-values calculated using 1-way analysis of variance.

Table 6. Postoperative improvement (ΔPROM scores)

Values are presented as mean±standard deviation.

PROM, patient-reported outcome measure; ASA PS, American Society of Anesthesiologists physical status; VAS, visual analogue scale; ODI, Oswestry Disability Index; SF-12 PCS, 12-item Short Form health survey physical composite score; PROMIS PF, Patient-Reported Outcomes Measurement Information System physical function.

p-values calculated using 1-way analysis of variance.

Table 7. MCID achievement

Values are presented as number (%).

ASA PS, American Society of Anesthesiologists physical status; MCID, minimum clinically important difference; PROM, patient-reported outcome measure; ASA PS, American Society of Anesthesiologists physical status; VAS, visual analogue scale; ODI, Oswestry Disability Index; SF-12 PCS, 12-item Short Form health survey physical composite score; PROMIS PF, Patient-Reported Outcomes Measurement Information System physical function.

p<0.05, statistically significant differences.

p-values calculated using simple logistic regression.